STING1 and melanoma: Additionally, two cycles of IV administration of a STING agonist in a lipid nanoparticle together with CpG ODN increased the number of CD11bhighCD27low memory NK cells in a murine melanoma model, thereby highlighting the potential effect of STING agonists on memory NK cells and the possible importance of administering multiple doses.[84] Furthermore, combining a TLR7/8 agonist (‘522′) and DMXAA decreased tumor volume and M2 macrophages while NK cells were increased.[85] Notably, pre‐activation of the STING pathway suppressed the TLR9‐mediated IFN production from plasmacytoid DCs.